This leaves patients with non-eosinophilic or neutrophilic asthma without adequate options. ‘Can we truly help people with ...

There is an urgent need for improved diagnostic tools and targeted therapies to address the gap in care for patients with ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with ...

GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that targets ...

China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...

GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Saturday, January 4, 2025, 09:00 Hrs [IST] GSK plc announced ...

On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on ...

GSK (NYSE:GSK) has received Chinese regulatory approval for its drug Nucala, also known as mepolizumab, for the treatment of ...

Around 50% of asthma attacks and 30% of COPD attacks are "eosinophilic exacerbations ... SHAMAL that showed benralizumab could allow people with asthma to reduce or even stop their use ...

It is estimated that about 107 million people in China suffer from chronic ... adolescents aged 12 years and older with severe eosinophilic asthma as well as for adults with eosinophilic ...

For the majority of people with asthma, symptoms are linked to high levels of eosinophilic inflammation. To identify this, blood eosinophil levels and FeNO are useful. Where there is a positive ...